Drug Trial Radar · NCT01410890
Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease
Last checked: Nov 20, 2026Latest source record: Mar 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
21
Actual
Start
Nov 3, 2014
Primary completion
Nov 20, 2020
Study completion Nov 20, 2020
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Aug 5, 2011
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
* The primary objective of this study was to characterize the pharmacokinetics (PK) of alglucosidase alfa manufactured at the 4000 L scale in participants who had a confirmed diagnosis of Pompe disease. * A secondary objective of this study was to evaluate and explore the relationship between anti-recombinant human acid alpha-glucosidase antibody titers and the PK of alglucosidase alfa.
Conditions
- Pompe Disease
- Glycogen Storage Disease Type II (GSD II)
Interventions
alglucosidase alfaBiological
Intravenous (IV) infusion of 20mg/kg body weight every other week (qow)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of Alglucosidase AlfaTime frame: Pre-dose and at 1, 2, 4, 8, 12, and 24 hours Post-dose on Day 1
- Pharmacokinetics: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Alglucosidase AlfaTime frame: Pre-dose and at 1, 2, 4, 8, 12, and 24 hours Post-dose on Day 1
- Pharmacokinetics: Area Under the Plasma Concentration-Time Curve (AUC) of Alglucosidase AlfaTime frame: Pre-dose and at 1, 2, 4, 8, 12, and 24 hours Post-dose on Day 1
- Pharmacokinetics: Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-last) of Alglucosidase AlfaTime frame: Pre-dose and at 1, 2, 4, 8, 12, and 24 hours Post-dose on Day 1
- Pharmacokinetics: Terminal Elimination Half-life (T1/2) of Alglucosidase AlfaTime frame: Pre-dose and at 1, 2, 4, 8, 12, and 24 hours Post-dose on Day 1
- Pharmacokinetics: Total Systemic Clearance (CL) of Alglucosidase AlfaTime frame: Pre-dose and at 1, 2, 4, 8, 12, and 24 hours Post-dose on Day 1
- Pharmacokinetics: Volume of Distribution at Steady State (Vss) of Alglucosidase AlfaTime frame: Pre-dose and at 1, 2, 4, 8, 12, and 24 hours Post-dose on Day 1
Locations
12 sites in 6 countries. Site status is shown where the registry gives one.
Investigational Site Number 840008
Valhalla, New York
Investigational Site Number 840007
Cincinnati, Ohio
Investigational Site Number 840005
Salt Lake City, Utah
Investigational Site Number 840003
Fairfax, Virginia
Investigational Site Number 1028
Sofia, Bulgaria
Investigational Site Number 356001
New Delhi, India
Investigational Site Number 356002
Vellore, India
Investigational Site Number 643001
Moscow, Russia
Investigational Site Number 643002
Moscow, Russia
Investigational Site Number 804001
Kiev, Ukraine
Investigational Site Number 826003
Birmingham, United Kingdom
Investigational Site Number 826002
Salford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.